Difference between revisions of "Team:BGU Israel"

Line 60: Line 60:
 
                               <li><img src="https://static.igem.org/mediawiki/2015/5/5c/BGU_home_slider_team4.jpg" /></li>
 
                               <li><img src="https://static.igem.org/mediawiki/2015/5/5c/BGU_home_slider_team4.jpg" /></li>
 
                               <li><img src="https://static.igem.org/mediawiki/2015/6/6a/BGU_home_slider_team5.jpg" /></li>
 
                               <li><img src="https://static.igem.org/mediawiki/2015/6/6a/BGU_home_slider_team5.jpg" /></li>
 +
                              <li><img src="https://static.igem.org/mediawiki/2015/b/b6/BGU_home_slider_team6.jpg" /></li>
 
                           </ul>
 
                           </ul>
 
          
 
          

Revision as of 01:12, 17 September 2015

Team:BGU Israel
Achievements
Project description
Design
Results
Practices and Polices

The Boomerang system:

Despite recent treatment advancements, cancer is still a major cause of mortality worldwide. One of the fundamental problems preventing the development of effective therapy is the difficulty to target cancer cells exclusively.
In Boomerang, we're engineering a genetic device based on a simple concept of AND logic gate: the activation of our CRISPR/Cas9-based system is dependent on the existence of two cancer-specific promoters that control the expression of Cas9 and gRNA, and the combination of these two will occur only in cancer cells. CRISPR/Cas9 system allows several applications of Boomerang: 1) disruption of genes essential for cancer survival; and 2) activation of suicide genes, or color proteins for cancer cell detection (e.g., for complete surgical removal).
Our system can be potentially designed according to unique characteristics of a patient's tumor, paving the way to personalized medicine. We hope that our strategy will change the approach to cancer treatments.